Global Breast cancer Companies
Companies in the breast cancer sector play a crucial role in the development of diagnostic tools, therapeutic interventions, and supportive technologies aimed at addressing the various aspects of breast cancer.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Latest Breast Cancer Companies Update
Genentech/Roche (US/Switzerland) Received FDA approval for Kadcyla® (trastuzumab emtansine) in September 2023 for the treatment of HER2-positive early breast cancer, offering a potential alternative to traditional chemotherapy.
AstraZeneca (UK) Announced positive Phase 3 trial results for Lynparza® (olaparib) in July 2023, demonstrating its efficacy in preventing the recurrence of breast cancer in BRCA-mutated patients.
Pfizer (US) Launched Ibrance® (palbociclib) in combination with Aromasin® (exemestane) in May 2023 for the treatment of postmenopausal women with HR-positive, HER2-negative advanced breast cancer, providing another treatment option for this specific group.
Verastem Oncology (US) Received Breakthrough Therapy Designation from the FDA for duvvaloran in June 2023 for the treatment of locally advanced or metastatic urothelial carcinoma, highlighting potential applications in other cancer types like breast cancer.
Illumina (US) Introduced the TruSight Oncology 500 next-generation sequencing (NGS) assay in October 2023, offering a comprehensive panel for detecting mutations in 523 cancer-related genes, including those relevant to breast cancer, facilitating personalized treatment decisions.
List of Breast Cancer Key Companies in the Market
- Mylan Laboratories
- AstraZeneca
- Celltrion
- Bristol-Myers Squibb
- FRESENIUS KABI
- Eisai Co. Ltd
- Baxter Healthcare Corporation
- GlaxoSmithKline
- Pfizer Inc.
- Halozyme Inc.
Global Breast cancer Market Highlights:
Global Breast cancer Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
